New pill YR011 enters first human safety trial
NCT ID NCT07285967
First seen Jan 09, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This Phase 1 trial tests the safety and tolerability of a new oral drug called YR011 in 64 healthy volunteers. The drug blocks a potassium channel involved in immune cell activity. Participants receive either YR011 or a placebo in single or multiple doses. The study aims to find out if the drug is safe enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YR011 (also called PA032, a Kv1.3 potassium channel blocker)
What this could lead to
If this early trial shows the drug is safe, it could lead to further studies testing YR011 for conditions involving the immune system, such as autoimmune diseases.
What could go wrong
This is a very early Phase 1 trial with only 64 healthy people. It is designed to check safety, not effectiveness. The drug may cause side effects or fail in later trials.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.